Myanmar version of the HIV stigma scale

📜
Abstract

The Myanmar version of the HIV stigma Scale (HIVSS-M-3) is a specialized psychometric instrument designed to quantify the multifaceted nature of stigma experienced by individuals living with HIV in Myanmar. Recognizing that existing Western-centric measures often fail to capture the unique cultural and religious nuances of Southeast Asian populations, researchers synthesized elements from Berger's established HIV stigma Scale and an Indian variant. The resulting tool integrates culturally specific dimensions, such as karma-related religious concerns, alongside traditional metrics of internalized and enacted stigma.

By providing a rigorously validated, localized measure, this instrument enables public health professionals and behavioral scientists to better understand the psychosocial barriers hindering HIV treatment adherence in a high-prevalence, resource-limited setting. The scale's development utilized a robust combination of Classical Test Theory and Rasch analysis, ensuring that the final 35-item instrument offers precise, culturally sensitive measurement free from demographic biases.

📊 Psychometric Scorecard

Items Count
35
Structure
Multidimensional
Cronbach's α
0.72
Validation Country
📍 Myanmar

Translation Method: Cultural adaptation and translation

Authors

🏛 School of Nursing, Fujian Medical University, Fuzhou, China

🏛 School of Nursing, University of California Los Angeles, Los Angeles, CA, USA

🏛 Department of Social Work, National Taiwan University, Taipei, Taiwan

🏛 Advocacy, Human Right & Technical Services Department, Secretariat Office Myanmar Positive Group (MPG), Yangon, Myanmar

🏛 Advocacy, Human Right & Technical Services Department, Secretariat Office Myanmar Positive Group (MPG), Yangon, Myanmar

🏛 Department of Public Health, Ministry of Health and Sports, National AIDS Program, Naypyitaw, Myanmar

🏛 Department of Medical Research, Deputy Director, Health System Research Division, Yangon, Myanmar

🏛 Department of Public Health, Ministry of Health and Sports, National AIDS Program, Naypyitaw, Myanmar

Purpose

In the realm of health psychology and infectious disease management, stigma remains one of the most formidable barriers to testing, treatment adherence, and overall quality of life. While global initiatives aim to rapidly scale up HIV care, progress in countries like Myanmar is frequently derailed by pervasive social discrimination. The development of the HIVSS-M-3 addresses a critical measurement gap: the absence of a culturally calibrated, Burmese-language tool to assess HIV-related stigma.

For clinicians and researchers, having a localized instrument is essential for designing targeted psychosocial interventions. It allows practitioners to pinpoint exactly which types of stigma—whether rooted in healthcare settings, family dynamics, or religious beliefs—are most prevalent, thereby guiding the allocation of limited public health resources more effectively and supporting global targets for HIV eradication.

Construct

The psychological construct of HIV-related stigma encompasses the prejudice, discounting, and discrimination directed at individuals based on their serostatus. Theoretically, this construct is highly multidimensional, typically divided into enacted stigma (actual experiences of discrimination), anticipated stigma (fear of future discrimination), and internalized stigma (endorsement of negative societal beliefs about oneself).

The HIVSS-M-3 expands upon this traditional framework by incorporating cultural specificity. It measures six distinct facets: personalized stigma, concerns regarding public attitudes, negative self-image, healthcare provider discrimination, disclosure anxieties, and religious concerns. The inclusion of religious concerns is particularly noteworthy, as it captures the intersection of local Buddhist ideologies—such as the concept of karma and past-life transgressions—with the psychological experience of chronic illness.

Validity

To establish the scale's construct validity, researchers evaluated its relationship with theoretically adjacent psychological variables. Consistent with established psychometric literature, higher scores on the stigma scale demonstrated a robust positive correlation with depressive symptoms (r = 0.60) and a strong negative correlation with perceived social support (r = -0.77). This convergent validity evidence confirms that the instrument accurately captures the deleterious psychosocial impact of stigma.

Furthermore, the researchers employed Rasch analysis to verify structural validity at the item level. The infit and outfit mean squares fell within the acceptable 0.68 to 1.40 range, indicating that the items appropriately fit the underlying latent trait model. Crucially, the analysis revealed no differential item functioning (DIF) across gender or educational levels, ensuring the scale measures stigma equitably across diverse demographic subgroups.

Convergent & Discriminant Validation Correlations

Reference Instrument Correlation Coefficient (r)
Center for Epidemiological Studies Depression Scale (CES-D) r=0.60
Medical Outcomes Study–Social Support Survey (MOS-SSS) r=-0.77

Reliability

The internal consistency of the refined 35-item scale proved to be exceptionally strong, meeting rigorous psychometric standards for both research and potential clinical application. Across the six subscales, Cronbach's alpha coefficients ranged from 0.72 to 0.95, indicating that the items within each domain reliably measure the same underlying concept.

Additionally, the application of Item Response Theory via Rasch analysis provided person reliability indices of 3.40 and 1.53, alongside separation indices of 0.92 and 0.70. These metrics demonstrate the instrument's robust capacity to consistently differentiate between respondents experiencing varying severities of stigma, confirming its utility as a precise measurement tool.

Factor Analysis

The structural architecture of the scale was determined through a comprehensive exploratory factor analysis (EFA). Initial testing confirmed the data's suitability for dimension reduction. Using parallel analysis, the researchers extracted a six-factor solution that accounted for an impressive 68.23% of the total variance in stigma scores.

During the iterative refinement process, items were subjected to strict retention criteria based on both Classical Test Theory and Rasch modeling. Items exhibiting factor loadings below 0.40, significant cross-loadings across multiple domains, or poor fit statistics were systematically eliminated. This rigorous psychometric pruning reduced the original 47-item pool to a highly optimized 35-item structure, ensuring that each retained item strongly and uniquely contributes to its respective factor.

Subscales

Subscale Items Description
Personalized stigma 29, 18, 33, 38, 35, 36, 32, 28, 24, 34 Measures direct, personal experiences of rejection, distancing, or discrimination from others due to HIV status.
Concerns with public attitudes about HIV 10, 20, 16, 9, 40, 14, 5 Assesses the individual's perception of societal prejudice, stereotypes, and general negative attitudes toward people living with HIV.
Negative self-image 23, 12, 7, 15, 2, 3 Evaluates internalized stigma, including feelings of guilt, shame, and self-depreciation related to having HIV.
Healthcare provider's stigma 46, 45, 44, 47 Captures experiences of discrimination, refusal of care, or mistreatment specifically within medical and hospital settings.
Disclosure concerns 17, 37, 6, 25, 19 Measures the anxiety, effort, and fear associated with keeping one's HIV status a secret to avoid anticipated discrimination.
Religious concerns 41, 43, 42 Assesses culturally specific stigma tied to religious beliefs, such as attributing HIV infection to bad karma or past-life sins.

Instrument

Test Type Self-report questionnaire
Format 35 items, self-report response format
Scoring Item scores are summed to yield subscale and total stigma scores
Language Burmese
Population Medical patients
Age Group Adults (18 years and older)
Administration Online administration via REDCap
Completion Time Approximately 30 minutes for the full survey battery

Myanmar version of the HIV stigma scale Items

📋 Items are currently not available

The individual items of this scale are not publicly available. Researchers interested in using this instrument should contact the original authors directly to request the scale materials.

Sample

The validation sample consisted of 156 adults living with HIV in Myanmar, recruited via a closed Facebook group using random sampling. The mean age of participants was 28.92 years (SD = 17.32). The sample was predominantly male (62.2%) and of Bamar ethnicity (76.9%), with an average of 9.57 years living with HIV.

📚
References
41 references
  1. Tun MMM, Mongkolchati A, Aung MN, Aung MU, Laosee O. Determinants of quality of life among people living with HIV in the hilly region of Myanmar. J HIVAIDS Soc Serv. 2019;18(4):367–81. https://doi.org/10.1080/15381501.2019.1659900. 🔗 https://doi.org/10.1080/15381501.2019.1659900
  2. UNAIDS. AIDSinfo. http://aidsinfo.unaids.org/ Accessed April 2020.
  3. Aung T, Oo HN. World AIDS Day 2018. Update. The Global New Light of Myanmar; 2018 https://wwwgnlmcommm/world-aids-day-2018/ Accessed April 2020.
  4. UNAIDS. Fast-track: ending the AIDS epidemic by 2030; 2014. https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
  5. Corless IB, Hoyt AJ, Tyer-Viola L, Sefcik E, Kemppainen J, Holzemer WL. 90-90-90-plus: maintaining adherence to antiretroviral therapies. AIDS Patient Care STDs. 2017;31(5):227–36. https://doi.org/10.1089/apc.2017.0009. 🔗 https://doi.org/10.1089/apc.2017.0009
  6. Mahajan AP, Sayles JN, Patel VA, Remien RH, Sawires SR, Ortiz DJ, et al. Stigma in the HIV/ AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67–79. https://doi.org/10.1097/01.aids.0000327438.13291.62. 🔗 https://doi.org/10.1097/01.aids.0000327438.13291.62
  7. Kamitani E, Chen JL, Portillo C, Tokumoto J, Dawson-Rose C. Shortened and culturally appropriate HIV stigma scale for Asians living with HIV in the United States: psychometric analysis. J Assoc Nurses AIDS Care. 2018;29(4):560–9. https://doi.org/10.1016/j.jana.2018.02.007. 🔗 https://doi.org/10.1016/j.jana.2018.02.007
  8. Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. Am J Public Health. 2013;103(5):813–21. https://doi.org/10.2105/AJPH.2012.301069. 🔗 https://doi.org/10.2105/AJPH.2012.301069
  9. Jeyaseelan L, Kumar S, Mohanraj R, Rebekah G, Rao D, Manhart LE. Assessing HIV/AIDS stigma in South India: validation and abridgement of the Berger HIV stigma scale. AIDS Behav. 2013;17(1):434–43. https://doi.org/10.1007/s10461-011-0128-3. 🔗 https://doi.org/10.1007/s10461-011-0128-3
  10. Bharat S. A systematic review of HIV/AIDS-related stigma and discrimination in India: current understanding and future needs. SAHARA J. 2011;8(3):138–49. https://doi.org/10.1080/17290376.2011.9724996. 🔗 https://doi.org/10.1080/17290376.2011.9724996
  11. Sweeney SM, Vanable PA. The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature. AIDS Behav. 2016;20(1):29–50. https://doi.org/10.1007/s10461-015-1164-1. 🔗 https://doi.org/10.1007/s10461-015-1164-1
  12. Aung NM, Hanson J, Kyi TT, Htet ZW, Cooper DA, Boyd MA, et al. HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Res Ther. 2017;14(1):10. https://doi.org/10.1186/s12981-017-0137-z. 🔗 https://doi.org/10.1186/s12981-017-0137-z
  13. Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 70(5):539–45. 🔗 https://doi.org/10.1097/PSY.0b013e3181777a5f
  14. Aung, EC. Myanmar’s HIV patients shunned despite progress in treatment. Thomson Reuters Foundation News. 2015. https://news.trust.org/item/20151201002830-wi66q/ Accessed April 2020.
  15. Tang A. People with HIV in Asia ejected from hospitals, women sterilised study. Thomson Reuters Foundation News. 2016. https://news.trust.org/item/20160315125313-600q2/ Accessed April 2020.
  16. Oo HN, Hone S, Fujita M, Maw-Naing A, Boonto K, Jacobs M, et al. Evolution of the health sector response to HIV in Myanmar: progress, challenges and the way forward. J Virus Erad. 2016;2(Suppl 4):20–6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337409/. https://doi.org/10.1016/S2055-6640(20)31095-5. 🔗 https://doi.org/10.1016/S2055-6640(20)31095-5
  17. Aye WL, Puckpinyo A, Peltzer K. Non-adherence to anti-retroviral therapy among HIV infected adults in Mon State of Myanmar. BMC Public Health. 2017;17(1):391. https://doi.org/10.1186/s12889-017-4309-5. 🔗 https://doi.org/10.1186/s12889-017-4309-5
  18. Than MW, Zaw NT, Minn K, Saw YM, Kiriya J, Jimba M, et al. Assessing depressive symptoms among people living with HIV in Yangon City, Myanmar: does being a member of self-help group matter? PLoS One. 2021;16(3):e0248807. https://doi.org/10.1371/journal.pone.0248807. 🔗 https://doi.org/10.1371/journal.pone.0248807
  19. Aung S, Hardy N, Chrysanthopoulou S, Htun N, Kyaw A, Tun MS, et al. Evaluation of peer-to-peer HIV counseling in Myanmar: a measure of knowledge, adherence, and barriers. AIDS Care. 2021;21:1–9. https://doi.org/10.1080/09540121.2021.1902929. 🔗 https://doi.org/10.1080/09540121.2021.1902929
  20. Reinius M, Rao D, Manhart LE, Wiklander M, SvedhemV PJ, et al. Differential item functioning for items in Berger’s HIV stigma scale: an analysis of cohorts from the Indian, Swedish, and US contexts. Qual Life Res. 2018;27(6):1647–59. https://doi.org/10.1007/s11136-018-1841-4. 🔗 https://doi.org/10.1007/s11136-018-1841-4
  21. Earnshaw VA, Chaudoir SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. AIDS Behav. 2009;13(6):1160–77. https://doi.org/10.1007/s10461-009-9593-3. 🔗 https://doi.org/10.1007/s10461-009-9593-3
  22. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;2(6):518–29. https://doi.org/10.1002/nur.10011. 🔗 https://doi.org/10.1002/nur.10011
  23. Reinius M, Wettergren L, Wiklander M, Svedhem V, Ekström AM, Eriksson LE. Development of a 12-item short version of the HIV stigma scale. Health Qual Life Outcomes. 2017;15(1):115. https://doi.org/10.1186/s12955-017-0691-z. 🔗 https://doi.org/10.1186/s12955-017-0691-z
  24. Bunn JY, Solomon SE, Miller C, Forehand R. Measurement of stigma in people with HIV: a reexamination of the HIV stigma scale. AIDS Ed Prev. 2007;19(3):198–208. https://doi.org/10.1521/aeap.2007.19.3.198. 🔗 https://doi.org/10.1521/aeap.2007.19.3.198
  25. Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV + youth. J Adolesc Health. 2007;40(1):96–8. https://doi.org/10.1016/j.jadohealth.2006.08.001. 🔗 https://doi.org/10.1016/j.jadohealth.2006.08.001
  26. Hernansaiz-Garrido H, Alonso-Tapia J. Internalized HIV stigma and disclosure concerns: development and validation of two scales in Spanish-speaking populations. AIDS Behav. 2017;21(1):93–105. https://doi.org/10.1007/s10461-016-1305-1. 🔗 https://doi.org/10.1007/s10461-016-1305-1
  27. Steward WT, Herek GM, Ramakrishna J, Bharat S, Chandy S, Wrubel J, et al. HIV-related stigma: adapting a theoretical framework for use in India. Soc Sci Med. 2008;67(8):1225–35. https://doi.org/10.1016/j.socscimed.2008.05.032. 🔗 https://doi.org/10.1016/j.socscimed.2008.05.032
  28. Adler SE. The influence of Burmese Buddhist understandings of suffering on the subjective experience and social perceptions of schizophrenia. Doctoral dissertation, Case Western Reserve University. p. 42–3.
  29. Spiro M. Buddhism and society: a great tradition and its Burmese vicissitudes. Berkeley: University of California Press; 1982. https://doi.org/10.1525/9780520341982. 🔗 https://doi.org/10.1525/9780520341982
  30. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651–7. https://doi.org/10.1007/s11136-011-9960-1. 🔗 https://doi.org/10.1007/s11136-011-9960-1
  31. von Elm E, Altman DG, Egger M, PocockSJ GPC, Vandenbroucke JP, STROBE initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9. https://doi.org/10.1016/j.ijsu.2014.07.013. 🔗 https://doi.org/10.1016/j.ijsu.2014.07.013
  32. Brislin RW. Back-translation for cross-cultural research. J Cross-Cult Psychol. 1970;1(3):187–216. https://doi.org/10.1177/135910457000100301. 🔗 https://doi.org/10.1177/135910457000100301
  33. Jones PS, Lee JW, Phillips LR, Zhang XE, Jaceldo KB. An adaptation of Brislin’s translation model for cross-cultural research. Nurs Res. 2001;50(5):300–4. https://doi.org/10.1097/00006199-200109000-00008. 🔗 https://doi.org/10.1097/00006199-200109000-00008
  34. Huang FF, Yang Q, Han XY, Zhang JP, Lin T. Development and validation of a self-efficacy scale for postoperative rehabilitation management of lung cancer patients. Psycho-Oncol. 2017;26(8):1172–80. https://doi.org/10.1002/pon.4296. 🔗 https://doi.org/10.1002/pon.4296
  35. Wolfe EW, Smith EV. Instrument development tools and activities for measure validation using Rasch models: part II–validation activities. J Appl Measure. 2007;8(2):204–34.
  36. Linacre JM. Winsteps Rasch Measurement Computer Program User’s Guide. Beaverton: Winsteps.com; 2015.
  37. Xu Z, Wu S, Li W, Dou Y, Wu Q. The Chinese Catquest-9SF: validation and application in community screenings. BMC Ophthalmol. 2018;18(1):77. https://doi.org/10.1186/s12886-018-0743-0. 🔗 https://doi.org/10.1186/s12886-018-0743-0
  38. Johnson C, Aaronson N, Blazeby JM, Bottomley A, Fayers P, Koller M, et al. Guidelines for developing questionnaire modules. 4th ed. Brussels: EORTC: On behalf of the Quality of Life Group; 2011.
  39. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012. 🔗 https://doi.org/10.1016/j.jclinepi.2006.03.012
  40. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8(2):94–104. https://doi.org/10.1111/j.1524-4733.2005.04054.x. 🔗 https://doi.org/10.1111/j.1524-4733.2005.04054.x
  41. Day A. Religion and the individual: belief, practice, identity: Routledge; 2016. https://doi.org/10.4324/9781315604848. 🔗 https://doi.org/10.4324/9781315604848

Cite this article

Mohammed looti (2026). Myanmar version of the HIV stigma scale. PSYCHOLOGICAL SCALES. Retrieved from https://scales.arabpsychology.com/s/myanmar-version-of-the-hiv-stigma-scale/

Mohammed looti. "Myanmar version of the HIV stigma scale." PSYCHOLOGICAL SCALES, 14 Aug. 2026, https://scales.arabpsychology.com/s/myanmar-version-of-the-hiv-stigma-scale/.

Mohammed looti. "Myanmar version of the HIV stigma scale." PSYCHOLOGICAL SCALES, 2026. https://scales.arabpsychology.com/s/myanmar-version-of-the-hiv-stigma-scale/.

Mohammed looti (2026) 'Myanmar version of the HIV stigma scale', PSYCHOLOGICAL SCALES. Available at: https://scales.arabpsychology.com/s/myanmar-version-of-the-hiv-stigma-scale/.

[1] Mohammed looti, "Myanmar version of the HIV stigma scale," PSYCHOLOGICAL SCALES, vol. X, no. Y, ص Z-Z, August, 2026.

Mohammed looti. Myanmar version of the HIV stigma scale. PSYCHOLOGICAL SCALES. 2026;vol(issue):pages.

× Figure
PDF
Scroll to Top